Qualigen Therapeutics, Inc. (NASDAQ:QLGN) Short Interest Up 505.1% in November

Qualigen Therapeutics, Inc. (NASDAQ:QLGN) was the recipient of a significant increase in short interest in November. As of November 15th, there was short interest totalling 94,400 shares, an increase of 505.1% from the October 31st total of 15,600 shares. Based on an average trading volume of 82,400 shares, the short-interest ratio is currently 1.1 days. Currently, 14.1% of the company’s shares are short sold.

Qualigen Therapeutics Stock Performance

QLGN traded up $0.19 during trading hours on Wednesday, hitting $4.66. 33,767 shares of the company’s stock were exchanged, compared to its average volume of 94,028. Qualigen Therapeutics has a 1-year low of $3.34 and a 1-year high of $39.13. The stock’s 50-day moving average is $6.60 and its two-hundred day moving average is $9.61.

Qualigen Therapeutics Company Profile

Qualigen Therapeutics, Inc, a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints.